Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702102 · ClinicalTrials.gov registry record · Phase 2
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
A Phase 2 study of Dementia With Lewy Bodies and Diffuse Lewy Body Disease, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT02702102 is a Phase 2 study of Dementia With Lewy Bodies and Diffuse Lewy Body Disease that has completed, run by Columbia University. The registered enrollment target is 5 participants, below the 471-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02702102, a Phase 2 study of Dementia With Lewy Bodies and Diffuse Lewy Body Disease, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body. 11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies. 11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.
Conditions Studied
Interventions
- DRUG 11C-PBR28
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-12 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702102
The ClinicalTrials.gov registry entry for NCT02702102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 471-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (99% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dementia With Lewy Bodies appearing as the primary indexed condition, and to 1 intervention - of which 11C-PBR28 is the first listed.
NCT02702102 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02702102 about?
NCT02702102 is a clinical study titled "Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies". This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body. 11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to s...
What is the current status of trial NCT02702102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-12. Estimated completion is 2019-09-04.
What conditions does trial NCT02702102 study?
This clinical trial studies the following conditions: Dementia With Lewy Bodies, Diffuse Lewy Body Disease, Parkinson's Disease Dementia.
What interventions are being tested in trial NCT02702102?
The interventions under investigation include: 11C-PBR28 (DRUG).
Who is sponsoring clinical trial NCT02702102?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02702102 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia With Lewy Bodies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
RECRUITING · Phase 2
-
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
RECRUITING · Phase 2
-
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
COMPLETED · Phase 2
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
-
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
RECRUITING · Phase 4
-
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.